

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7276556

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NEIL SONIN DHAWAN	11/23/2020
JAMES ABELLERA BLAIR	11/20/2020
ROBERT B. PERNI	11/21/2020
RECEIVING PARTY DATA	
Name:	TOTUS MEDICINES INC.
Street Address:	700 MAIN STREET
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17694592
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	zippatentdocketingmailbox-us@cooley.com,
Correspondent Name:	COOLEY LLP, ATTN: PATENT GROUP
Address Line 1:	1299 PENNSYLVANIA AVE, NW
Address Line 2:	SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	TOTU-006/03US 343340-2067
NAME OF SUBMITTER:	STEPHANIE R. MCCABE
SIGNATURE:	/Stephanie R. McCabe/
DATE SIGNED:	04/13/2022
Total Attachments: 3	
source=TOTU-006_03US_ExecutedAssignment#page1.tif	
source=TOTU-006_03US_ExecutedAssignment#page2.tif	
source=TOTU-006_03US_ExecutedAssignment#page3.tif	

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to TOTUS MEDICINES INC., having a place of business at 700 Main Street, Cambridge, MA 02139, ("ASSIGNEE"), for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. PCT/US2020/051491, entitled "THERAPEUTIC CONJUGATES", filed on September 18, 2020 which claims priority to US Provisional Application No. 62/902,554 filed September 19, 2019 and US Provisional Application No. 63/078,055 filed September 14, 2020.

2. The entire worldwide right, title, and interest in and to:
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not

Title: THERAPEUTIC CONJUGATES
Filed: September 18, 2020
Application No: PCT/US20/51491

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date 11-23-20

Signature 

Name Neil Sonin Dhawan

Date 2020-11-26

Signature 

Name James Apellera Blair

Date _____

Signature _____

Name Robert B. Perni

The undersigned acknowledges and accepts this assignment on behalf of TOTUS MEDICINES INC.

Date 11-23-20

Signature 

Neil Dhawan, CEO, TOTUS MEDICINES INC.

Title: THERAPEUTIC CONJUGATES
Filed: September 18, 2020
Application No: PCT/US20/31493

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date _____ Signature _____
Name Neil Sonin Dhawan

Date _____ Signature _____
Name James Abellera Blair

Date Nov 21, 2020 Signature 
Name Robert B. Perni

The undersigned acknowledges and accepts this assignment on behalf of TOTUS MEDICINES INC.

Date 11-23-2020 Signature 
Name Neil Dhawan, CEO, TOTUS MEDICINES INC.